Cerity Partners’s Oragenics OGEN Stock Holding History

Cerity Partners’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	-$1.07K	–	1884
2022 Q4	$1.07K	Buy	+6	New	+$2.12K	﹤0.01%	1483

Other funds holding OGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

WWM

Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return

Cerity Partners's OGEN Position: Q1 2023 in Review

Cerity Partners sold out of Oragenics (OGEN) in Q1 2023, closing a stake of 6 shares — an estimated $1.07K sold.

Cerity Partners first reported a position in OGEN in Q4 2022 and held it in 1 quarter. The position peaked at $1.07K in Q4 2022. 10 funds tracked by Wall St. Rank hold OGEN as of Q1 2023.

Cerity Partners reported no remaining Oragenics position as of Q1 2023 after selling out during the quarter.
Cerity Partners sold 6 Oragenics shares in Q1 2023, an estimated $1.07K.
Cerity Partners first reported a position in Oragenics in Q4 2022 and held it in 1 quarter.
Cerity Partners's Oragenics position peaked at $1.07K in Q4 2022.
10 funds tracked by Wall St. Rank held Oragenics as of Q1 2023.

Based on Cerity Partners's 13F filing for Q1 2023, filed 11 May 2023.